These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28617618)

  • 1. Value-Based Calculators in Cancer: Current State and Challenges.
    Nabhan C; Feinberg BA
    J Oncol Pract; 2017 Aug; 13(8):499-506. PubMed ID: 28617618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
    Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why clinical oncologists should talk about the price of cancer drugs.
    Berlinger N
    Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
    [No Abstract]   [Full Text] [Related]  

  • 4. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How much is the life of a cancer patient worth? A pharmaco-economic perspective.
    Simoens S; Dooms M
    J Clin Pharm Ther; 2011 Jun; 36(3):249-56. PubMed ID: 21545607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
    Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
    J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
    Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
    J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
    [No Abstract]   [Full Text] [Related]  

  • 11. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 13. Obstacles to affordable cancer treatments.
    Dusetzina SB; Muluneh B; Khan T; Richards KL; Keating NL
    N C Med J; 2014; 75(4):257-60. PubMed ID: 25046090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of cancer treatments: a review of the methods.
    Brown J
    Clin Oncol (R Coll Radiol); 1999; 11(2):78-83. PubMed ID: 10378631
    [No Abstract]   [Full Text] [Related]  

  • 15. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
    Schafer J; Galante D; Shafrin J
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Problem of Cancer Drugs Costs: A Payer Perspective.
    Newcomer LN
    Cancer J; 2020; 26(4):287-291. PubMed ID: 32732670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to Capturing Value in Oncology.
    Walter E
    Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care.
    Malin JL
    J Clin Oncol; 2020 Feb; 38(4):367-371. PubMed ID: 31804871
    [No Abstract]   [Full Text] [Related]  

  • 20. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.